Core Viewpoint - The article discusses the effectiveness of GLP-1 receptor agonists in addressing both obesity and diabetes, highlighting their dual role in controlling blood sugar levels and promoting weight loss [5][7][19]. Group 1: Understanding GLP-1 Receptor Agonists - GLP-1 is a gut hormone that enhances insulin secretion, suppresses glucagon release, and delays gastric emptying, contributing to blood sugar control and appetite suppression [7][8]. - The first GLP-1 receptor agonist, exenatide, was derived from the saliva of the Gila monster, and subsequent drugs like liraglutide and semaglutide have been developed with improved efficacy and dosing schedules [8][9]. Group 2: Clinical Efficacy of Liraglutide - Liraglutide has been shown to effectively control blood sugar and promote weight loss in both diabetic and non-diabetic obese patients, with significant results from clinical trials [9][10]. - In a study published in 2009, participants using liraglutide lost between 4.8 kg to 7.2 kg over 20 weeks, compared to 2.8 kg and 4.1 kg in the placebo and orlistat groups, respectively [10][11]. - Long-term studies indicated that liraglutide users maintained an average weight loss of 7.8 kg after two years, with some participants losing up to 10.3 kg [12]. Group 3: Semaglutide as a New Contender - Semaglutide, introduced in 2017, requires only weekly injections and has demonstrated an average weight loss of 15% in clinical trials, significantly outperforming previous weight loss medications [14][16]. - In the STEP 1 trial, participants lost an average of 14.9% of their body weight, with over one-third losing more than 20% [16]. - The STEP series of trials confirmed semaglutide's effectiveness in reducing weight and improving metabolic health, leading to its FDA approval for obesity management in 2021 [19]. Group 4: Future Prospects - Oral formulations of semaglutide are being explored, showing promising results in reducing blood sugar and weight, although currently approved only for diabetes treatment [20][22]. - The PIONEER trials demonstrated significant weight loss and HbA1c reduction in patients using oral semaglutide, indicating its potential for broader applications in obesity management [22][23].

Group 1 - A recent study from the University of California, San Diego, found that women with type 2 diabetes taking metformin have a 30% higher chance of living to 90 years or older compared to those using sulfonylureas [1] - Metformin is evolving from a traditional diabetes medication to a potential anti-aging treatment, with increasing evidence suggesting its role in longevity [1] - The study establishes a link between metformin monotherapy and the likelihood of living to 90 years or older, filling a research gap in this area [1] Group 2 - Key companies involved in metformin production include Koyuan Pharmaceutical, which produces metformin hydrochloride raw materials and tablets for type 2 diabetes treatment [2] - Another company, Teva Pharmaceutical, produces metformin sustained-release tablets that reduce liver glucose production and improve insulin sensitivity [2]